Last reviewed · How we verify
NCT06652464
Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis
trial in Disease Activity in 90 participants. Completed in 15 November 2024.
1 November 2024
Quick facts
| Lead sponsor | Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 1 August 2024 |
| Primary completion | 1 November 2024 |
| Estimated completion | 15 November 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Disease Activity — all drugs for Disease Activity →
- Remission of Ulcerative Colitis — all drugs for Remission of Ulcerative Colitis →
- Ulcerative Colitis Flare — all drugs for Ulcerative Colitis Flare →
Sponsor
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Who can join
Adults 18 to 80, any sex, with Disease Activity or Remission of Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Specialized pro-resolving mediators (SPMs), which are typically thought to be formed via consecutive steps of oxidation of polyenoic fatty acids, have been shown to suppress inflammation and promote timely resolution of inflammation. They are mainly divided into four categories: lipoxins, resolvins, protectins, and maresins. The study will compare Maresin-1 and Resolvin-D1 levels in ulcerative colitis patients with those in the control group.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Serum Maresin-1 and Resolvin-D1 Levels as Non-Invasive Biomarkers for Monitoring Disease Activity in Ulcerative Colitis.
Demirci S, Sezer S. · · 2025 · cited 4× · PMID 40218184 · DOI 10.3390/diagnostics15070834
Verify or expand the search:
- PubMed search for NCT06652464
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Disease Activity
Currently open trials in the same condition.
- NCT06945549 — Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging · recruiting
- NCT07359326 — The Effect of Cold Application in Patients With Rheumatoid Arthritis · NA · active not recruiting
Other Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital trials
Trials by the same sponsor.
- NCT07394816 — Can Ultrasound-Guided Fascial Plane Blocks Reduce Postoperative Pulmonary Complications After Major Abdominal Surgery? · not yet recruiting
- NCT07509697 — Artificial Intelligence-Based Evaluation of Chest X-Rays in Ventilator-Associated Pneumonia · completed
- NCT07440095 — Mortality Predictors in Patients 80+ After Major Abdominal Surgery: Role of Frailty and Physiological Reserve · not yet recruiting
- NCT07392086 — Comparison of FCV and VCV in One-Lung Ventilation · recruiting
- NCT07325617 — Tracking AI/LLM Literacy and Knowledge in Urology Outpatients (TALK-U) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06652464 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
- Last refreshed: 7 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06652464.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing